BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...Capital Management, alongside existing investors BVF Partners, Casdin Capital, Mubadala Capital and series B lead Nextech Invest...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...Targeting SolutionsNumber of employees: 50Funds raised: $136 millionInvestors: The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest...
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...Wellington Management Co. The existing investors joining OrbiMed is continuing to back the company are Nextech Invest...
BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

...seven years at precision oncology company Blueprint Medicines Inc. (NASDAQ:BPMC). Investing alongside Third Rock were Nextech Invest...
...Corporate partners: None Number of employees: 19 Funds raised: $86 million Investors: Third Rock Ventures, Nextech Invest...
BioCentury | Mar 18, 2020
Finance

March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

...$45 million in a series B round led by The Column Group with participation by Nextech Invest...
BioCentury | Mar 12, 2020
Finance

Silverback raises $78.5M series B to send innate immunity activating therapies to clinic

...potential of the therapy to stimulate the innate immune system through systemic delivery. New investors Nextech Invest...
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...stealth Thursday with $74.5 million in an untranched series B from new investors OrbiMed Advisors, Nextech Invest...
...will join Kinnate's board, along with Foresite's Brett Zbar and Michael Rome. Elizabeth S. Eaton, Staff Writer Nextech Invest OrbiMed...
BioCentury | Dec 5, 2019
Financial News

Black Diamond raises $85M series C, shoots to enter clinic next half

...the round, as did Versant and fellow existing investors New Enterprise Associates, RA Capital Management, Nextech Invest...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...PMV Pharmaceuticals Inc. raised $62 million in a series C round led by new investors Nextech Invest...
BioCentury | Nov 6, 2019
Financial News

A2 emerges with $57M series A, engineered T cells for solid tumors

...The Column Group led the tranched round, with participation by Vida Ventures, Samsara BioCapital and Nextech Invest...
Items per page:
1 - 10 of 79
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...Capital Management, alongside existing investors BVF Partners, Casdin Capital, Mubadala Capital and series B lead Nextech Invest...
BioCentury | Oct 9, 2020
Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...Targeting SolutionsNumber of employees: 50Funds raised: $136 millionInvestors: The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest...
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

...Wellington Management Co. The existing investors joining OrbiMed is continuing to back the company are Nextech Invest...
BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

...seven years at precision oncology company Blueprint Medicines Inc. (NASDAQ:BPMC). Investing alongside Third Rock were Nextech Invest...
...Corporate partners: None Number of employees: 19 Funds raised: $86 million Investors: Third Rock Ventures, Nextech Invest...
BioCentury | Mar 18, 2020
Finance

March 17 Quick Takes: Tempus, Circle, Immatics, Exuma, CFIUS

...$45 million in a series B round led by The Column Group with participation by Nextech Invest...
BioCentury | Mar 12, 2020
Finance

Silverback raises $78.5M series B to send innate immunity activating therapies to clinic

...potential of the therapy to stimulate the innate immune system through systemic delivery. New investors Nextech Invest...
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

...stealth Thursday with $74.5 million in an untranched series B from new investors OrbiMed Advisors, Nextech Invest...
...will join Kinnate's board, along with Foresite's Brett Zbar and Michael Rome. Elizabeth S. Eaton, Staff Writer Nextech Invest OrbiMed...
BioCentury | Dec 5, 2019
Financial News

Black Diamond raises $85M series C, shoots to enter clinic next half

...the round, as did Versant and fellow existing investors New Enterprise Associates, RA Capital Management, Nextech Invest...
BioCentury | Nov 21, 2019
Financial News

Nov. 20 Financial Quick Takes: Diagnostics play Lucence raises series A; plus Novo-Broad, PMV, Phoenix, Winterlight and BMS-Celgene

...PMV Pharmaceuticals Inc. raised $62 million in a series C round led by new investors Nextech Invest...
BioCentury | Nov 6, 2019
Financial News

A2 emerges with $57M series A, engineered T cells for solid tumors

...The Column Group led the tranched round, with participation by Vida Ventures, Samsara BioCapital and Nextech Invest...
Items per page:
1 - 10 of 79